Relay Therapeutics, Inc
- Biotech or pharma, therapeutic R&D
Relay Therapeutics (RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients.
Key disclosed programs include:
RLY-2608 - the first mutant-selective PI3Kα inhibitor for Breast Cancer and Vascular Malformations
RLY-8161 - the first NRASs-selective molecule designed to drive greater efficacy in NRAS-driven tumors
Preclinical Fabry program - the first non-inhibitory αGal chaperone
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}